The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (DD) - Masimo LHC Ltd/LiDCO Group Plc

3 Nov 2020 11:42

RNS Number : 1150E
Masimo LHC Limited
03 November 2020
 

FORM 8 (DD)

 

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Masimo LHC Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

-

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

LiDCO Group Plc

(d) Status of person making the disclosure:

e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)

OFFEROR

(e) Date dealing undertaken:

2 November 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

 

Class of relevant security:

 

LiDCO Group PLC 0.5 pence Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,250,000

0.51

NIL

0.00

(2) Cash-settled derivatives:

 

NIL

0.00

NIL

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

NIL

0.00

NIL

0.00

 

TOTAL:

1,250,000

0.51

NIL

0.00

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

GBP

0.5 pence ordinary

Purchase

 

525,000

0.1181

0.5 pence ordinary

Purchase

 

350,000

0.1182

0.5 pence ordinary

Purchase

 

375,000

0.12

 

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

3 November 2020

Contact name:

Rick Fishel

Telephone number:

+1 949 297 7366

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DCCKKNBNDBDDCDK
Date   Source Headline
29th Mar 20167:00 amRNSRegulatory approval in China
24th Mar 20167:00 amRNSMaster distribution agreement & other distributors
15th Mar 20167:00 amRNSLaunching the new LiDCOunity at ISICEM Brussels
4th Mar 20164:31 pmRNSHolding(s) in Company
2nd Mar 20165:06 pmRNSBlock Listing Review
8th Feb 20167:00 amRNSTrading update
2nd Feb 20163:52 pmRNSHolding(s) in Company
23rd Nov 20157:00 amRNSMaster distribution agreement
16th Nov 20154:35 pmRNSDirector's Dealing
13th Oct 20158:30 amRNSUS purchasing agreement with US hospitals group
13th Oct 20157:00 amRNSHalf Yearly Report
23rd Sep 201510:03 amRNSNotice of Results
2nd Sep 20157:00 amRNSTrading update and notice of results
17th Aug 20157:00 amRNSFormal appointment of Chief Executive Officer
31st Jul 20157:00 amRNSBlock Listing Review
15th Jun 20152:27 pmRNSBoard appointment and grant of share options
11th Jun 20157:00 amRNSJapan reimbursement for LiDCOrapidv2 disposables
13th May 201511:45 amRNSResult of AGM
6th May 20157:01 amRNSCEO and Board Appointment
5th May 20151:32 pmRNSPosting of Annual Report & Notice of AGM
23rd Apr 20157:00 amRNSLiDCO data presented at London Forum
14th Apr 20157:00 amRNSHolding in Company
1st Apr 201512:49 pmRNSDirector/PDMR Shareholding
31st Mar 20157:01 amRNSLIDCOrapid v2 cleared for sale in Japan
31st Mar 20157:00 amRNSFinal Results
17th Mar 20157:00 amRNSShowcasing Portable LiDCO Stand System at ISICEM
10th Mar 20157:03 amRNSNotice of Results
2nd Mar 20156:14 pmRNSHolding(s) in Company
17th Feb 20157:00 amRNSFurther clinical support for LiDCOrapid
12th Feb 20157:00 amRNSTrading update and notice of results
30th Jan 201512:20 pmRNSBlock listing review
17th Dec 20142:39 pmRNSHolding(s) in Company
1st Dec 20142:39 pmRNSHolding(s) in Company
17th Nov 20147:00 amRNSFurther clinical support for LiDCOrapid
12th Nov 20145:15 pmRNSHolding(s) in Company
7th Nov 201412:03 pmRNSHolding(s) in Company
3rd Nov 20145:49 pmRNSHolding(s) in Company
16th Sep 20147:01 amRNSBoard Announcement
16th Sep 20147:00 amRNSHalf Yearly Report
21st Aug 201411:39 amRNSNotice of Results
18th Aug 20147:00 amRNSTrading update
31st Jul 20141:46 pmRNSBlock Listing Review
30th Jul 20147:00 amRNSFurther clinical support for LiDCO products
11th Jun 201412:45 pmRNSResult of AGM
11th Jun 201411:49 amRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
23rd May 20141:51 pmRNSPosting of Annual Report & Notice of AGM
22nd May 20144:01 pmRNSHolding(s) in Company
21st May 20147:00 amRNSMonitors Link with NantHealth's DeviceConX System
20th May 20147:00 amRNSResults of the OPTIMISE study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.